Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)

This study has been completed.
Sponsor:
Collaborators:
German Federal Ministry of Education and Research
Information provided by:
Collaborative Group for Adrenocortical Carcinoma Treatment
ClinicalTrials.gov Identifier:
NCT00094497
First received: October 19, 2004
Last updated: May 14, 2012
Last verified: May 2012
  Purpose

The purpose of this study is to determine whether treatment with etoposide, doxorubicin, cisplatin and mitotane (EDP/M) prolongs survival as compared to streptozotocin and mitotane (Sz/M) in patients with advanced adrenocortical carcinoma (ACC) whose disease is not amenable to complete surgical resection.


Condition Intervention Phase
Carcinoma, Adrenal Cortical
Drug: Etoposide
Drug: Doxorubicin
Drug: Cisplatin
Drug: Streptozotocin
Drug: Mitotane
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment

Resource links provided by NLM:


Further study details as provided by Collaborative Group for Adrenocortical Carcinoma Treatment:

Primary Outcome Measures:
  • Overall survival [ Time Frame: At the final analysis ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to progression (TTP) [ Time Frame: At each evaluation (every 8 weeks) ] [ Designated as safety issue: No ]
  • Quality of life as measured by QLQ-C30 [ Time Frame: at each evaluation ] [ Designated as safety issue: Yes ]
  • Best overall response rate and duration of response [ Time Frame: At each evaluation (every 8 weeks) ] [ Designated as safety issue: No ]
  • Number of disease-free patients [ Designated as safety issue: No ]
  • Impact of reaching mitotane blood levels between 14-20 mg/l in both arms on survival and overall response rate [ Designated as safety issue: No ]
  • TTP of both regimens as second line treatment in case of failure of the other initial regime [ Designated as safety issue: No ]
  • Pharmakinetics of mitotane (substudy) [ Time Frame: 11 time points in the first 12 weeks ] [ Designated as safety issue: No ]
    To study the relationship between mitotane dose (daily and cumulative) and mitotane plasma concentrations using one of two pre-defined treatment regimens (high-dose and low-dose).


Enrollment: 300
Study Start Date: June 2004
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Detailed Description:

The Firm-ACT trial is the first ever conducted randomized controlled phase III trial in adrenocortical carcinoma (ACC), a rare malignancy with poor prognosis. It will provide results leading to the establishment of an urgently needed gold standard chemotherapy regimen for patients with locally advanced or metastatic ACC. To this end the trial compares the two most promising drug combinations investigated in phase II trials, considered by the "International Consensus Conference on Adrenal Cancer" (Ann Arbor/USA, 2003) as valuable first line treatments for advanced ACC. The first regimen consists of etoposide, doxorubicin, cisplatin plus mitotane (EDP-M), the second regiment employs streptozotocin plus mitotane (Sz-M). Over a period of five years this international trial will include 300 patients with advanced ACC from different European countries. Blood mitotane concentrations will be monitored, aiming at drug levels between 14 - 20 mg/L. Patients not responding to the first line treatment will be switched to the alternative regimen. The primary objective of this trial is to investigate whether EDP-M given as first line treatment will prolong survival as compared to Sz-M. Secondary endpoints are quality of life, time to progression, best overall response rate and duration of response. In addition, the trial evaluates the role of reaching therapeutic mitotane serum concentrations for survival and tumour response and assesses the value of the two alternative treatment regimens as second line therapy in advanced ACC. Moreover, the FIRM-ACT trial will generate a lasting structural basis for successful future trials in ACC.

In a substudy of 40 patients a detailed analysis of the pharmacokinetics of oral mitotane will be analysed. Two different mitotane treatment regimens ("low dose" vs. "high dose") will be compared.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of adrenocortical carcinoma
  • Locally advanced or metastatic disease not amenable to radical surgery resection (Stage III-IV)
  • Radiologically monitorable disease
  • ECOG performance status 0-2
  • Life expectancy > 3 months
  • Age ≥18 years
  • Adequate bone marrow reserve (neutrophils > 1500/mm3 and platelets > 100,000/mm3)
  • Effective contraception in pre-menopausal female and male patients
  • Patient's written informed consent
  • Ability to comply with the protocol procedures (including availability for follow-up visits)
  • Previous palliative surgery, radiotherapy or radiofrequency ablation is acceptable as long as radiologically monitorable disease is verifiable afterwards.

Exclusion Criteria:

  • History of prior malignancy, except for cured non-melanoma skin cancer, curatively in situ cervical carcinoma, or other cancers treated with no evidence of disease for at least five years.
  • Previous cytotoxic chemotherapy for adrenocortical carcinoma
  • Renal insufficiency (serum creatinine ≥2 mg/dl or creatinine clearance ≤ 50 ml/min)
  • Hepatic insufficiency (serum bilirubin ≥2 x the institutional upper limit of normal range and/or serum transaminases ≥ 3 x the institutional upper limit of normal range; exception: in patients on mitotane, transaminase levels up to 5 x the institutional upper limit of normal range are acceptable)
  • Pregnancy or breast feeding
  • Known hypersensitivity to any drug included in the treatment protocol
  • Presence of active infection
  • Any other severe clinical condition that in the judgment of the local investigator would place the patient at undue risk or interfere with the study completion
  • Decompensated heart failure (ejection fraction <50%), myocardial infarction or revascularization procedure during the last 6 months, unstable angina pectoris, and uncontrolled cardiac arrhythmia
  • Current treatment with other experimental drugs and/or previous participation in clinical trials with other experimental agents for adrenocortical carcinoma
  • Prisoners
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00094497

Locations
United States, Maryland
National Cancer Institute - Center for Cancer Research
Bethesda, Maryland, United States
United States, Michigan
University of Michigan, Department of Internal Medicine
Ann Arbor, Michigan, United States, 48109
Australia
Royal Adelaide Hospital
Adelaide, Australia, SA 5000
Austria
University of Graz
Graz, Austria, 8036
France
Clinique Marc Linquette
Lille, France
Centre Leon Berard
Lyon, France
Hospital de Marseille la timone
Marseille, France, 13385
Cochin Hospital
Paris, France, 75679
Hospital Bordeaux haut leveque
Pessac, France, 33600
Institut Gustave Roussy
Villejuif, France, 94805
Germany
Charité-University, Dept. of Endocrinology; Campus Benjamin Franklin
Berlin, Germany
Charité-Universitätsmedizin Berlin - Campus Mitte
Berlin, Germany
Dept. of Medicine III
Dresden, Germany
University of Duesseldorf, Dept. of Endocrrinology
Duesseldorf, Germany, 40001
Zentrum für Innere Medizin - Endokrinologie des Universitätsklinikum Essen
Essen, Germany
Endokrinologie Medizinische Hochschule Hannover
Hannover, Germany
Otto-von-Guericke University; Dept. of Endocrinology
Magdeburg, Germany, 39120
Dept of Medicine I
Mainz, Germany
University of Munich, Dept. of Internal Medicine (Innenstadt)
Munich, Germany, 80336
University of Wuerzburg - Dept. of Medicine
Wuerzburg, Germany, 97080
Italy
University of Turin, Dept of Internal Medicine
Orbassano, Italy, 10043
Clinica Endocrinologica, Università di Padova, Azienda Ospedaliera di Padova
Padova, Italy
Netherlands
Academisch Medisch Centrum; Dept. of Endocrinology
Amsterdam, Netherlands, 1105 AZ
Vrije Universiteit Medisch Centrum
Amsterdam, Netherlands, 1007
Maxima Medisch Centrum; Dept. of Internal Medicine
Eindhoven, Netherlands, 5631 BM
University Hospital Groningen; Dept. of Internal Medine
Groningen, Netherlands, 9700
Leiden University Medical Center
Leiden, Netherlands
Sweden
Department of Oncology, Sahlgrenska University Hospital
Gothenburg, Sweden
Department of Oncology, Linköping University Hospital
Linköping, Sweden
Department of Medicine, The Jubileum Institute, Lund University
Lund, Sweden
Dept of Surgery, Karolinska Hospital, Stockholm
Stockholm, Sweden
Uppsala University Hospital - Dept of Medical Sciences
Uppsala, Sweden, 751 85
Sponsors and Collaborators
Collaborative Group for Adrenocortical Carcinoma Treatment
German Federal Ministry of Education and Research
Investigators
Study Chair: Britt Skogseid, MD Uppsala University Hospital
Principal Investigator: Martin Fassnacht, MD University of Würzburg
  More Information

Additional Information:
Publications:
Responsible Party: Martin Fassnacht + Britt Skogseid, University of Würzburg + University of Uppsala
ClinicalTrials.gov Identifier: NCT00094497     History of Changes
Obsolete Identifiers: NCT00924144
Other Study ID Numbers: CO-ACT-001
Study First Received: October 19, 2004
Last Updated: May 14, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Sweden: Medical Products Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Italy: Ministry of Health
Netherlands: Independent Ethics Committee
Australia: Department of Health and Ageing Therapeutic Goods Administration

Additional relevant MeSH terms:
Adrenocortical Carcinoma
Carcinoma
Adenocarcinoma
Adrenal Cortex Diseases
Adrenal Cortex Neoplasms
Adrenal Gland Diseases
Adrenal Gland Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on November 27, 2014